The prognostic role of CD5 negativity in B-cell chronic lymphocytic leukemia: A case-control study

Haematologia

Volumn 32, Issue 3, 2002, Pages 209-218

  Efstathiou, S ^a   Tsioulos, D ^a   Zacharos, I ^a   Tsiakou, A ^a   Mastorantonakis, S ^a   Salgami, E ^a   Katirtzoglou, N ^a   Psarra, A ^b   Roussou, P ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

CD5; Chronic lymphocytic leukaemia; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CD19 ANTIGEN; CD2 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CD8 ANTIGEN; CD9 ANTIGEN; CHLORAMBUCIL; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE PHOSPHATE; GLYCOPROTEIN P 15095; INTERLEUKIN 2 RECEPTOR; PREDNISONE; VINCRISTINE;

ADULT; AGE; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; GENDER; HEMOLYTIC ANEMIA; HUMAN; LABORATORY TEST; LYMPH NODE METASTASIS; MALE; MONONUCLEAR CELL; NONHODGKIN LYMPHOMA; PATHOGENESIS; PHYSICAL EXAMINATION; PROGNOSIS; SPLENECTOMY; SPLENOMEGALY; T LYMPHOCYTE; THORAX RADIOGRAPHY;

AGED; AGED, 80 AND OVER; ANEMIA, HEMOLYTIC; ANTIGENS, CD5; AUTOIMMUNITY; CASE-CONTROL STUDIES; FEMALE; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, B-CELL, CHRONIC; LYMPH NODES; MALE; MIDDLE AGED; PROGNOSIS; SPLENOMEGALY; SURVIVAL RATE;

EID: 0036963740     PISSN: 00176559     EISSN: None     Source Type: Journal    
DOI: 10.1163/15685590260461020     Document Type: Article

References (24)

1. International Workshop on Chronic Lymphocytic Leukemia. Recommendations for diagnosis, stage and response criteria, Ann. Intern. Med. 110, 236 (1989).
2. Lydard, P. M., Youinou, P. Y., Cooke, A., CD5 positive B cells in rheumatoid arthritis and chronic lymphocytic leukemia, Immunol. Today 8, 37 (1987).
3. + B cells, Clin. Immunol. Immunopathol. 56, 135 (1990).
4. + B cells in autoimmune disease and lymphoid malignancy, Clin. Immunol. Immunopathol. 59, 173 (1991).
5. Kurec, A. S., Threatte, G. A., Gottlieb, A. J., Smith, J. R., Anderson, J., Davey, F. R., Immunophenotyping subclassification of chronic lymphocytic leukemia, Br. J. Haematol. 81, 45 (1992).
6. SPSS, Statistical Package for the Social Sciences, Windows version, release 10.0. SPSS Inc., Chicago (2000).
7. Kaplan, E. L., Meier, P., Non-parametric estimation for incomplete observations, J. Am. Stat. Assoc. 53, 457 (1958).
8. Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., Smith, P. G., Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples, Br. J. Cancer 35, 1 (1977).
9. Telek, B., Rejto, L., Mezei, G., Karaszi, E., Kappelmayer, J., Balazs, M., Kiss, A., Ujj, G., Rak, K., Udvardy, M., Molecular biology examination in chronic lymphocytic leukemia, Orv. Hetil. 142, 833 (2001).
10. Scrivener, S., Kaminski, E. R., Demaine, A., Prentice, A. G., Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation, Br. J. Haematol. 112, 959 (2001).
11. Foon, K. A., Rai, K. R., Gale, R. P., Chronic lymphocytic leukaemia: new insights into biology and therapy, Ann. Intern. Med. 113, 525 (1990).
12. Finn, W. G., Singleton, T. P., Schnitzer, B., Ross, C. W., Stoolman, L. M., Adhesion molecule expression in CD5-negative/CD10-negative chronic B-cell leukemias: comparison with non-Hodgkin's lymphomas and CD5-positive B-cell chronic lymphocytic leukemia, Hum. Pathol. 32, 66 (2001).
13. Freedman, A. S., Nadler, L. M., B cell development in chronic lymphocytic leukemia, Semin. Hematol. 24, 230 (1987).
14. Cartron, G., Linassier, C., Bremond, J. L., Desablens, B., Georget, M. T., Fimbel, B., Luthier, F., Dutel, J. L., Lamagnere, J. P., Colombat, P., CD5 negative B-cell chronic lympdocytic leukemia: clinical and biological features of 42 cases, Leuk. Lymphoma 31, 209 (1998).
15. Geisler, C. H., Larsen, J. K., Hansen, N. E., Hansen, M. M., Christensen, B. E., Lund, B., Nielsen, H., Plesner, T., Thorling, K., Andersen, E., Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia, Blood 78, 1795 (1991).
16. De Rossi, G., Mauro, F. R., Lo Coco, F., Caruso, R., Niscola, P., Pasqualetti, D., Mandelli, F., CD5 negative lymphocytosis mimicking typical b-chronic lymphocytic leukemia. Description of 26 cases, Nouv. Rev. Fr. Hematol. 35, 451 (1993).
17. Kay, N. E., Peterson, L., Heterogeneity of CD5 membrane expression on B-chronic lymphocytic leukemia cells, Leuk. Lymphoma 5, 49 (1991).
18. Bassan, R., Pronesti, M., Buzzetti, M., Viero, P., Minetti, B., Comotti, B., Buelli, M., Barbui, T., Surface immunoglobulin intensitivity and p67 (CD5) antigen expression define different forms of B-cell chronic lymphocytic leukaemia, Haematologica 72, 221 (1987).
19. - CLL: an analysis of 26 cases, Nouv. Rev. Fr. Hematol. 33, 178 (1991).
20. + B-CLL and B PLL, Leuk. Lymphoma 16, 445 (1995).
21. Lydyard, P. M., Jewell, A. P., Jamin, C., Youinou, P. Y., CD5 B cells and B-cell malignancies, Curr. Opin. Hematol. 6, 30 (1999).
22. Molica, S., Prognostic value of biological variables in B-cell chronic lymphocytic leukemia. Can we improve upon clinical parameters?, Haematologica 82, 705 (1997).
23. Youinou, P., Pers, J. O., Jamin, C., Lydyard, P. M., CD5-positive B cells at the crossroads of B cell malignancy and nonorgan-specific autoimmunity, Pathol. Biol. (Paris) 48, 574 (2000).
24. Rawstron, A. C., Kennedy, B., Evans, P. A., Davies, F. E., Richards, S. J., Haynes, A. P., Russell, N. H., Hale, G., Morgan, G. J., Jack, A. S., Hillmen, P., Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy, Blood 98, 29 (2001).